临床可操作性耐受机制的研究进展

樊文梅; 石炳毅

doi:10.3969/j.issn.1674-7445.2015.06.002

临床可操作性耐受机制的研究进展

doi: 10.3969/j.issn.1674-7445.2015.06.002

樊文梅,
石炳毅^,

100093 北京, 解放军第309医院器官移植研究所北京市器官移植与免疫调节重点实验室

基金项目:

国家自然科学基金 81270509

详细信息

作者简介:
樊文梅, 女, 副研究员, 博士后, 硕士研究生导师。现任解放军第309医院器官移植研究室副研究员、博士后, 导师为石炳毅教授, 第四军医大学细胞生物学专业硕士研究生导师。2004年6月毕业于北京大学医学部, 主要从事肝纤维化以及免疫耐受机制方面的研究。主持及参与国家自然科学基金4项, 参与科技部"十五"科技攻关项目、"十一五"科技支撑计划等项目的研究。兼任《International Journal of Infectious Disease》、《Cancer Epidemiology》等科学引文索引(Science Citation Index, SCI)杂志审稿专家。在《Journal of Gastroenterology》、《Digestive Disease and Science》、《Virus Genes》等SCI杂志以及《中华肝胆外科杂志》、《中华医学杂志》、《中华肝脏病杂志》等中文核心期刊发表论文20余篇

通讯作者:
石炳毅, Email:shibingyi@medmail.com.cn

中图分类号: R617;R392.4
计量
- 文章访问数: 58
- HTML全文浏览量: 72
- PDF下载量: 13
- 被引次数: 0
出版历程
- 收稿日期: 2015-08-10
- 网络出版日期: 2021-01-19
- 刊出日期: 2015-11-15

摘要

摘要: 器官移植是治疗终末期器官功能衰竭的有效手段, 但因终身服用免疫抑制剂而增加了肿瘤、感染等风险, 并有可能导致受者死亡和移植物失功。因此, 免疫耐受一直是移植研究工作者的最终目标。近年来发现在一些停用免疫抑制剂的受者中发生自发耐受现象, 称之为可操作性耐受。可操作性耐受是指在不使用免疫抑制剂的情况下, 至少1年以上无发生移植物排斥反应, 获得移植器官长期存活的现象。这一现象引起了移植免疫学家的广泛关注。本文介绍了临床可操作性耐受的临床监控及机制(包括调节性T细胞、B细胞和天然免疫细胞)方面的研究进展, 以期为后续研究提供参考。
- 可操作性耐受 /
- 免疫耐受 /
- 器官移植 /
- 排斥反应 /
- 预测 /
- 监控

HTML全文

参考文献(26)

[1]	Bishop GA, Ierino FL, Sharland AF, et al. Approaching the promise of operational tolerance in clinical transplantation[J]. Transplantation, 2011, 91(10):1065-1074. doi: 10.1097/TP.0b013e318215e742
[2]	Godfrey WR, Ge YG, Spoden DJ, et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures[J].Blood, 2004, 104(2):453-461. doi: 10.1182/blood-2004-01-0151
[3]	Bohne F, Martínez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation[J]. J Clin Invest, 2012, 122(1):368-382. doi: 10.1172/JCI59411
[4]	Schulz-Juergensen S, Marischen L, Wesch D, et al. Markers of operational immune tolerance after pediatric liver transplantation in patients under immunosuppression[J]. Pediatr Transplant, 2013, 17(4):348-354. doi: 10.1111/petr.2013.17.issue-4
[5]	Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants[J]. JAMA, 2012, 307(3):283-293. http://www.medscape.com/medline/abstract/22253395
[6]	Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence[J]. J Hepatol, 2006, 44(4):702-709. doi: 10.1016/j.jhep.2005.11.047
[7]	Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management:biopsy monitoring and working criteria for patients with operational tolerance[J]. Liver Transpl, 2012, 18(10):1154-1170. doi: 10.1002/lt.v18.10
[8]	Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients[J]. Curr Opin Organ Transplant, 2013, 18(3):345-353. doi: 10.1097/MOT.0b013e3283615d48
[9]	Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal[J]. Hepatol Res, 2012, 42(9):895-903. doi: 10.1111/hepr.2012.42.issue-9
[10]	Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts[J]. Liver Transpl, 2012, 18(11):1333-1342. doi: 10.1002/lt.v18.11
[11]	Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation[J]. Pediatr Transplant, 2012, 16(8):858-865. doi: 10.1111/j.1399-3046.2012.01781.x
[12]	Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation[J]. Transplantation, 2009, 87(4):606-614. doi: 10.1097/TP.0b013e318195a7cb
[13]	Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C[J]. Med Clin North Am, 2014, 98(1):17-38. doi: 10.1016/j.mcna.2013.10.011
[14]	Dugast E, Chesneau M, Soulillou JP, et al. Biomarkers and possible mechanisms of operational tolerance in kidney transplant patients[J]. Immunol Rev, 2014, 258(1):208-217. doi: 10.1111/imr.2014.258.issue-1
[15]	Moraes-Vieira PM, Silva HM, Takenaka MC, et al. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals[J]. Hum Immunol, 2010, 71(5):442-450. doi: 10.1016/j.humimm.2010.01.022
[16]	Louis S, Braudeau C, Giral M, et al. Contrasting CD25^hiCD4⁺T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance[J]. Transplantation, 2006, 81(3):398-407. doi: 10.1097/01.tp.0000203166.44968.86
[17]	Moraes-Vieira PM, Takenaka MC, Silva HM, et al. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation[J]. Clin Immunol, 2012, 142(2):117-126. doi: 10.1016/j.clim.2011.08.015
[18]	Braza F, Dugast E, Panov I, et al. Central role of CD45RA^- Foxp3^hi memory regulatory T cells in clinical kidney transplantation tolerance[J]. J Am Soc Nephrol, 2015, 26(8):1795-1805. doi: 10.1681/ASN.2014050480
[19]	Taubert R, Pischke S, Schlue J, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts[J]. Am J Transplant, 2012, 12(12):3425-3436. doi: 10.1111/ajt.2012.12.issue-12
[20]	Silva HM, Takenaka MC, Moraes-Vieira PM, et al. Preserving the B-cell compartment favors operational tolerance in human renal transplantation[J]. Mol Med, 2012, 18:733-743. https://www.researchgate.net/profile/Pedro_Moraes-Vieira/publication/221754660_Preserving_the_B-cell_compartment_favors_operational_tolerance_in_human_renal_transplantation/links/00b7d521f5706c728a000000.pdf
[21]	Coelho V, Saitovitch D, Kalil J, et al. Rethinking the multiple roles of B cells in organ transplantation[J]. Curr Opin Organ Transplant, 2013, 18(1):13-21. doi: 10.1097/MOT.0b013e32835c8043
[22]	Schulz-Juergensen S, Marischen L, Wesch D, et al. Markers of operational immune tolerance after pediatric liver transplantation in patients under immunosuppression[J]. Pediatr Transplant, 2013, 17(4):348-354. doi: 10.1111/petr.2013.17.issue-4
[23]	Bohne F, Londoño MC, Benítez C, et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans[J]. Sci Transl Med, 2014, 6(242):242ra81. doi: 10.1126/scitranslmed.3008793
[24]	Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans[J]. J Clin Invest, 2010, 120(6):1848-1861. doi: 10.1172/JCI39922
[25]	Danger R, Pallier A, Giral M, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant[J]. J Am Soc Nephrol, 2012, 23(4):597-606. doi: 10.1681/ASN.2011060543
[26]	Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance[J]. Proc Natl Acad Sci U S A, 2007, 104(39):15448-15453. doi: 10.1073/pnas.0705834104